Results 81 to 90 of about 8,735 (203)

Cleavage of von Willebrand factor by granzyme M destroys its factor VIII binding capacity. [PDF]

open access: yesPLoS ONE, 2011
Von Willebrand factor (VWF) is a pro-hemostatic multimeric plasma protein that promotes platelet aggregation and stabilizes coagulation factor VIII (FVIII) in plasma.
Martine J Hollestelle   +6 more
doaj   +1 more source

ADAMTS13 gene deletion enhances plasma high-mobility group box1 elevation and neuroinflammation in brain ischemia-reperfusion injury [PDF]

open access: yes, 2018
Highly adhesive glycoprotein von Willebrand factor (VWF) multimer induces platelet aggregation and leukocyte tethering or extravasation on the injured vascular wall, contributing to microvascular plugging and inflammation in brain ischemia-reperfusion. A
Akitake, Yoshiharu   +16 more
core  

The diagnosis and management of the haematologic manifestations of lupus [PDF]

open access: yes, 2016
Haematological manifestations in systemic lupus erythematosus (SLE) are frequently observed. They are diverse and range from mild to severe.
Castro, SG   +2 more
core   +1 more source

Transcriptional Regulation of Microglial Metabolic and Activation States by P2RY12

open access: yesGlia, Volume 73, Issue 12, Page 2464-2482, December 2025.
Main Points Transcriptionally, P2RY12‐deficient microglia show heightened metabolic activity, iron handling and oxidative stress at baseline. Upon LPS challenge, impaired glutathione antioxidant responses suggest increased vulnerability to ferroptosis. ABSTRACT Microglia are the resident immune cells of the CNS.
Aida Oryza Lopez‐Ortiz   +9 more
wiley   +1 more source

Anti-ADAMTS13 Autoantibodies in Immune-Mediated Thrombotic Thrombocytopenic Purpura

open access: yesAntibodies
Autoantibodies to ADAMTS13 are at the center of pathology of the immune-mediated thrombotic thrombocytopenic purpura. These autoantibodies can be either inhibitory (enzymatic function) or non-inhibitory, resulting in protein depletion.
Michael R. Snyder, Robert W. Maitta
doaj   +1 more source

Atypical hemolytic uremic syndrome : update on the complement system and what is new [PDF]

open access: yes, 2010
Atypical hemolytic uremic syndrome (aHUS) is a rare disease of microangiopathic hemolytic anemia, thrombocytopenia, and predominant renal impairment. It is characterized by the absence of Shiga toxin-producing bacteria as a triggering factor.
Dickenmann, Michael   +2 more
core   +1 more source

Soluble C5b‐9 (sC5b‐9) in Pediatrics—A Clinical Assessment

open access: yesJournal of Clinical Laboratory Analysis, Volume 39, Issue 23, December 2025.
The sc5b9 assay is a simple laboratory‐developed test that can be used in specific patients to monitor the course of disease, severity, or response to therapy. Future studies using this assay, which show excellent adaptability to a clinical laboratory, will reveal the multiple uses of testing for complement activation.
Ridwan B. Ibrahim   +3 more
wiley   +1 more source

ADAMTS9, a member of the ADAMTS family, in Xenopus development [PDF]

open access: yes, 2018
Extracellular matrix (ECM) remodeling by metalloproteinases is crucial during development. The ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin type I motifs) enzymes are secreted, multi-domain matrix-associated zinc metalloendopeptidases ...
Boerboom   +37 more
core   +1 more source

Rotational Thromboelastometry (ROTEM) Versus Conventional Coagulation Tests in Cirrhosis: Can We Reduce Plasma Transfusion Without ROTEM?

open access: yesJournal of Clinical Laboratory Analysis, Volume 39, Issue 24, December 2025.
ROTEM showed a strong correlation with conventional coagulation tests (CCTs) but failed to assess re‐balanced hemostasis. Similar to ROTEM, using higher CCT thresholds may help reduce unnecessary plasma transfusions before invasive procedures. ABSTRACT Background Periprocedural rotational thromboelastometry (ROTEM) could reduce transfusions while ...
Nuanrat Cheerasiri   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy